Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:ISR

Isoray (ISR) Stock Price, News & Analysis

Isoray logo

About Isoray Stock (NYSE:ISR)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.28
$0.42
52-Week Range
N/A
Volume
145,000 shs
Average Volume
290,697 shs
Market Capitalization
$54.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.

Receive ISR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Isoray and its competitors with MarketBeat's FREE daily newsletter.

ISR Stock News Headlines

French ISR Label Revamp Report
Why IsoRay (ISR) Is Plunging Today
Has Trump finally met his match?
Trump is making bold moves before even stepping back into the White House — securing border deals, brokering peace talks, and targeting sanctuary city funding. But according to 33-year Wall Street veteran Dylan Jovine, even Trump may not be able to fix what’s coming. Jovine believes there are five cracks forming in the U.S. economy — big enough to spark a 50% market crash, a 40% real estate plunge, and a surge in unemployment. That’s why he’s moved seven figures of his own money into a “safe haven” asset favored by names like Buffett, Musk, and Ackman. He’s released an emergency briefing explaining why the next 90 days could be critical for investors.
Why IsoRay (ISR) Stock Is Surging Today
IsoRay (ISR) Reports Q2 Loss, Misses Revenue Estimates
See More Headlines

ISR Stock Analysis - Frequently Asked Questions

Isoray, Inc. (NYSE:ISR) released its earnings results on Wednesday, November, 10th. The company reported ($0.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by $0.01. The firm had revenue of $2.56 million for the quarter, compared to analyst estimates of $2.58 million. Isoray had a negative net margin of 115.91% and a negative trailing twelve-month return on equity of 17.12%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Isoray investors own include Brainstorm Cell Therapeutics (BCLI), OPKO Health (OPK), Tesla (TSLA), Meta Platforms (META), Tonix Pharmaceuticals (TNXP) and Nano Dimension (NNDM).

Company Calendar

Last Earnings
11/10/2021
Today
4/23/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NYSE:ISR
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-7,270,000.00
Net Margins
-115.91%
Pretax Margin
-91.45%

Debt

Sales & Book Value

Annual Sales
$10.80 million
Price / Cash Flow
N/A
Book Value
$0.43 per share
Price / Book
N/A

Miscellaneous

Free Float
138,674,000
Market Cap
$54.57 million
Optionable
Not Optionable
Beta
1.48
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NYSE:ISR) was last updated on 4/23/2025 by MarketBeat.com Staff
From Our Partners